Yarrow Bioscience (NASDAQ:YARW – Get Free Report) and AquaBounty Technologies (NASDAQ:AQB – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.
Earnings and Valuation
This table compares Yarrow Bioscience and AquaBounty Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Yarrow Bioscience | $570,000.00 | 137.20 | -$26.48 million | ($14.64) | -2.00 |
| AquaBounty Technologies | $2.47 million | 2.38 | -$18.49 million | ($0.82) | -1.39 |
Profitability
This table compares Yarrow Bioscience and AquaBounty Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Yarrow Bioscience | -4,726.21% | -84.40% | -77.68% |
| AquaBounty Technologies | N/A | -147.07% | -28.73% |
Institutional and Insider Ownership
83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by company insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Yarrow Bioscience has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Yarrow Bioscience and AquaBounty Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Yarrow Bioscience | 1 | 0 | 2 | 0 | 2.33 |
| AquaBounty Technologies | 1 | 0 | 0 | 0 | 1.00 |
Yarrow Bioscience currently has a consensus price target of $58.00, indicating a potential upside of 98.02%. Given Yarrow Bioscience’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Yarrow Bioscience is more favorable than AquaBounty Technologies.
Summary
Yarrow Bioscience beats AquaBounty Technologies on 8 of the 14 factors compared between the two stocks.
About Yarrow Bioscience
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
About AquaBounty Technologies
AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.
Receive News & Ratings for Yarrow Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yarrow Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
